neurotrophic signaling comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
The Fat Duck is a fine dining restaurant in Bray, Berkshire, England, owned by the chef Heston Blumenthal. Housed in a 16th-century building, the Fat Duck opened on 16 August 1995. Although it originally served food similar to a French bistro, it soon acquired a reputation for precision and innovation, and has been at the forefront of many modern culinary developments, such as food pairing, flavour encapsulation and multi-sensory cooking. The number of staff in the kitchen increased from four when the Fat Duck opened to 42, resulting in a ratio of one kitchen staff member per customer. The Fat Duck gained its first Michelin star in 1999, its second in 2002 and its third in 2004, making it one of eight restaurants in the UK to earn three Michelin stars. In 2005, the World's 50 Best Restaurants named the Fat Duck the best restaurant in the world. It lost its stars in 2016 when it closed for renovation, but regained all three the following year. The Fat Duck is known for its tasting menu featuring dishes such as nitro-scrambled egg and bacon ice cream, an Alice in Wonderland–inspired mock turtle soup involving a bouillon packet made up to look like a fob watch dissolved in tea, and a dish called Sound of the Sea which includes an audio element. It has an associated laboratory where Blumenthal and his team develop new dish concepts. In 2009, the Fat Duck suffered from the largest norovirus outbreak ever documented at a restaurant, with more than 400 diners falling ill.
=== Enhanced oil recovery and carbon capture and storage === Supercritical carbon dioxide is used to enhance oil recovery in mature oil fields. At the same time, there is the possibility of using "clean coal technology" to combine enhanced recovery methods with carbon sequestration. The CO2 is separated from other flue gases, compressed to the supercritical state, and injected into geological storage, possibly into existing oil fields to improve yields. At present, only schemes isolating fossil CO2 from natural gas actually use carbon storage, (e.g., Sleipner gas field), but there are many plans for future CCS schemes involving pre- or post-combustion CO2. There is also the possibility to reduce the amount of CO2 in the atmosphere by using biomass to generate power and sequestering the CO2 produced.
Vacuum, used in small lamps. Provides best thermal insulation of the filament but does not protect against its evaporation. Used also in larger lamps where the outer bulb surface temperature has to be limited. Argon (93%) and nitrogen (7%), where argon is used for its inertness, low thermal conductivity and low cost, and the nitrogen is added to increase the breakdown voltage and prevent arcing between parts of the filament. Nitrogen, used in some higher-power lamps, e.g. projection lamps, and where higher breakdown voltage is needed due to proximity of filament parts or lead-in wires. Krypton, which is more advantageous than argon due to its higher atomic weight and lower thermal conductivity (which also allows use of smaller bulbs), but its use is hindered by much higher cost, confining it mostly to smaller-size bulbs. Krypton mixed with xenon, where xenon improves the gas properties further due to its higher atomic weight. Its use is however limited by its very high cost. The improvements by using xenon are modest in comparison to its cost. Hydrogen, in special flashing lamps where rapid filament cooling is required; its high thermal conductivity is exploited here. Halogen, a small amount mixed with inert gas which is used in halogen lamps, a distinct type of incandescent lamp. The gas fill must be free of traces of water, which greatly accelerates bulb blackening (see below). The gas layer close to the filament (called the Langmuir layer) is stagnant, with heat transfer occurring only by conduction.
Sources: en.wikipedia.org
=== Anhydrous structure === Anhydrous Dy(ClO4)3 crystallizes in the hexagonal crystal system, space group P63/m (No. 176). It is isostructural with the anhydrous perchlorates of La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Ho and Er, and belongs to a structure family related to the UCl3 type. In this structure the Dy3+ centres are nine-coordinate. The coordination environment is formed by oxygen atoms belonging to perchlorate groups, which act as multidentate ligands and generate a three-dimensional channel-containing framework. Across the lanthanide series, the lattice parameters decrease systematically because of the lanthanide contraction.
Jelleine is a family of peptides, isolated from the royal jelly of Apis mellifera iberiensis, a subspecies of the honey bee. This new family has the potential to be used in the development of new drugs.
== Constitutional and state laws == The Barger decision was made in the context of the then prevailing reserved State powers doctrine, which was itself overturned in 1920 in the Engineers case. Since 2005, Australian industrial relations laws, such as WorkChoices, have been primarily based on the corporations power in section 51(xx) of the Constitution, which enables labour laws to be of much wider reach, without the constraints imposed by the conciliation and arbitration power. The corporations power gives the federal parliament power to make laws with respect to "trading and financial corporations formed within the limits of the Commonwealth", as well as 'foreign' corporations.
dopamine β-monooxygenase dopamine β-hydroxylase membrane-associated dopamine β-monooxygenase (MDBH) soluble dopamine β-monooxygenase (SDBH) dopamine-B-hydroxylase 3,4-dihydroxyphenethylamine β-oxidase 4-(2-aminoethyl) pyrocatechol β-oxidase dopa β-hydroxylase dopamine β-oxidase dopamine hydroxylase phenylamine β-hydroxylase (3,4-dihydroxyphenethylamine) β-mono-oxygenase
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.